Quince Therapeutics Implements 1-for-10 Reverse Stock Split Effective April 10th
QNCX sits 97% above its 52-week low of $0.08 on elevated volume (12× avg).
Summary
Quince Therapeutics, Inc. announced the implementation of a 1-for-10 reverse stock split, effective April 10, 2026, with split-adjusted trading commencing April 13, 2026.
Key Events · Corporate Governance and Compliance · QNCX
-
Reverse Stock Split Implemented
The Company's board of directors approved the implementation of a 1-for-10 reverse stock split, previously authorized by stockholders on June 4, 2025.
-
Effective Date and Trading
The reverse stock split will be effective at 11:59 pm Eastern Time on April 10, 2026, with shares beginning to trade on a split-adjusted basis on the Nasdaq Global Select Market upon market open on April 13, 2026.
-
Impact on Shares and Derivatives
Every ten shares of common stock will be combined into one, resulting in approximately 16,300,795 shares outstanding post-split. Fractional shares will be paid cash in lieu, and all outstanding stock options and warrants will be proportionally adjusted.
Analysis · QNCX · Life Sciences
Quince Therapeutics is proceeding with a 1-for-10 reverse stock split, a move often undertaken by companies with low stock prices to meet exchange listing requirements and potentially attract a broader investor base. While the authorization for this split was previously disclosed in June 2025, this filing marks the definitive implementation, setting the effective date and the start of split-adjusted trading. This action, while necessary for compliance, typically carries a negative sentiment as it does not alter the company's underlying value and can sometimes be perceived as a sign of financial distress.
At the time of this filing, QNCX was trading at $0.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.2M. The 52-week trading range was $0.08 to $4.55. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.